Patents by Inventor Ori Lerman
Ori Lerman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7208485Abstract: The present invention provides a crystalline halobetasol propionate selected from the group consisting of halobetasol propionate having crystalline Form I characterized by power X-ray diffraction peak positions and intensities as set forth in Table 1 herein, halobetasol propionate having crystalline Form II characterized by power X-ray diffraction peak positions and intensities as set forth in Table 2 herein, halobetasol propionate having crystalline Form III characterized by power X-ray diffraction peak positions and intensities as set forth in Table 3 herein, halobetasol propionate having crystalline Form IV characterized by power X-ray diffraction peak positions and intensities as set forth in Table 4 herein, halobetasol propionate having crystalline Form V characterized by power X-ray diffraction peak positions and intensities as set forth in Table 5 herein, and halobetasol propionate having crystalline Form VI characterized by power X-ray diffraction peak positions and intensities as set forth in Table 6Type: GrantFiled: January 13, 2003Date of Patent: April 24, 2007Assignee: Chemagis Ltd.Inventors: Itai Adin, Yuri Futerman, Ori Lerman, Alexander Weisman, Chaim Ashkenazi, Joseph Kaspi
-
Publication number: 20060241159Abstract: The invention encompasses novel crystalline forms of zolmitriptan herein defined as Form B, D, C, E, F, G, H, I, J, K, M, N, O, P, Q, R, S, or Amorphous and to methods of making thereof. The invention also encompasses methods of making zolmitriptan crystalline Form A.Type: ApplicationFiled: June 19, 2006Publication date: October 26, 2006Inventors: Reuven Izsak, Ori Lerman, Tamas Koltai, Judith Aronhime, Michael Pinchasov, Hagit Eisen-Nevo
-
Publication number: 20060241160Abstract: The invention encompasses novel crystalline forms of zolmitriptan herein defined as Form B, D, C, E, F, G, H, I, J, K, M, N, O, P, Q, R, S, or Amorphous and to methods of making thereof. The invention also encompasses methods of making zolmitriptan crystalline Form A.Type: ApplicationFiled: June 19, 2006Publication date: October 26, 2006Inventors: Reuven Izsak, Ori Lerman, Tamas Koltai, Judith Aronhime, Michael Pinchasov, Hagit Eisen-Nevo
-
Publication number: 20060241158Abstract: The invention encompasses novel crystalline forms of zolmitriptan herein defined as Form B, D, C, E, F, G, H, I, J, K, M, N, O, P, Q, R, S, or Amorphous and to methods of making thereof. The invention also encompasses methods of making zolmitriptan crystalline Form A.Type: ApplicationFiled: June 19, 2006Publication date: October 26, 2006Inventors: Reuven Izsak, Ori Lerman, Tamas Koltai, Judith Aronhime, Michael Pinchasov, Hagit Eisen-Nevo
-
Publication number: 20060211751Abstract: The invention encompasses novel crystalline forms of zolmitriptan herein defined as Form B, D, C, E, F, G, H, I, J, K, M, N, O, P, Q, R, S, or Amorphous and to methods of making thereof. The invention also encompasses methods of making zolmitriptan crystalline Form A.Type: ApplicationFiled: November 21, 2005Publication date: September 21, 2006Inventors: Reuven Izsak, Ori Lerman, Tamas Koltai, Judith Aronhime, Michael Pinchasov, Hagit Eisen-Nevo
-
Publication number: 20060160785Abstract: Provided are processes for preparing crystalline forms of ezetimibe, such as ezetimibe Form A or Form B, for example, by precipitating ezetimibe from selected solvents. Alternatively, some forms may be transformed into different forms at elevated temperatures or under various humidity conditions, or by micronization. Also provided are micronized ezetimibe Form A, micronized ezetimibe Form B, and ezetimibe having a plate morphology. Pharmaceutical compositions containing these forms are particularly useful in reducing cholesterol in patients in need thereof.Type: ApplicationFiled: December 5, 2005Publication date: July 20, 2006Inventors: Judith Aronhime, Tamas Koltai, Guy Samburski, Ori Lerman, Reuven Izsak
-
Publication number: 20050215791Abstract: The invention encompasses the synthesis of aripiprazole from BBQ and DCP, and comprises mixing 7-(4-bromobutoxy)-3,4-dihydrocarbostyril (BBQ) and 1-(2,3-dichlorophenyl)piperazine hydrochloride (DCP) in the presence of at least one base and at least one organic solvent to form a reaction mixture; heating the reaction mixture for a sufficient amount of time to effect the reaction; and isolating aripiprazole. The invention also encompasses the use of phase transfer catalysts in synthesizing aripiprazole from BBQ and DCP.Type: ApplicationFiled: February 7, 2005Publication date: September 29, 2005Inventors: Ben-Zion Dolitzky, Ori Lerman
-
Patent number: 6844440Abstract: The invention provides a process for the preparation of a compound of the formula 6 comprising the hydrolysis and decarboxylation of a compound of the formula 5 according to the reaction: wherein R and R2 independently a C1-C4 alkyl group or an aralkyl group.Type: GrantFiled: June 11, 2003Date of Patent: January 18, 2005Assignee: Chemagis Ltd.Inventors: Ori Lerman, Joseph Kaspi, Oded Arad, Mohammed Alnabari, Yana Sery
-
Publication number: 20040138191Abstract: The present invention provides a crystalline halobetasol propionate selected from the group consisting of halobetasol propionate having crystalline Form I characterized by power X-ray diffraction peak positions and intensities as set forth in Table 1 herein, halobetasol propionate having crystalline Form II characterized by power X-ray diffraction peak positions and intensities as set forth in Table 2 herein, halobetasol propionate having crystalline Form III characterized by power X-ray diffraction peak positions and intensities as set forth in Table 3 herein, halobetasol propionate having crystalline Form IV characterized by power X-ray diffraction peak positions and intensities as set forth in Table 4 herein, halobetasol propionate having crystalline Form V characterized by power X-ray diffraction peak positions and intensities as set forth in Table 5 herein, and halobetasol propionate having crystalline Form VI characterized by power X-ray diffraction peak positions and intensities as set forth in Table 6Type: ApplicationFiled: January 13, 2003Publication date: July 15, 2004Applicant: CHEMAGIS LTD.Inventors: Itai Adin, Yuri Futerman, Ori Lerman, Alexander Weisman, Chaim Ashkenazi, Joseph Kaspi
-
Publication number: 20040138192Abstract: The present invention provides a crystalline halobetasol propionate selected from the group consisting of halobetasol propionate having crystalline Form I characterized by power X-ray diffraction peak positions and intensities as set forth in Table 1 herein, halobetasol propionate having crystalline Form II characterized by power X-ray diffraction peak positions and intensities as set forth in Table 2 herein, halobetasol propionate having crystalline Form III characterized by power X-ray diffraction peak positions and intensities as set forth in Table 3 herein, halobetasol propionate having crystalline Form IV characterized by power X-ray diffraction peak positions and intensities as set forth in Table 4 herein, halobetasol propionate having crystalline Form V characterized by power X-ray diffraction peak positions and intensities as set forth in Table 5 herein, and halobetasol propionate having crystalline Form VI characterized by power X-ray diffraction peak positions and intensities as set forth in Table 6Type: ApplicationFiled: December 5, 2003Publication date: July 15, 2004Applicant: CHEMAGIS LTD.Inventors: Itai Adin, Yuri Futerman, Ori Lerman, Alexander Weisman, Chaim Ashkenazi, Joseph Kaspi
-
Patent number: 6747163Abstract: The invention provides a process for the preparation and isolation of compound of formula 2, comprising the following steps: oxidizing Flumethasone dissolved in a tetrahydrofuran-water mixture with periodic acid at a temperature lower than 30° C.; cooling the reaction mixture to a temperature lower than 10° C.; adding an antisolvent precooled to a temperature lower than 10° C.; and separating the precipitated crystal by filtration, whereby there is obtained a compound of formula 2 in a yield of at least 98% and of a chromatographic purity of at least 99%.Type: GrantFiled: April 4, 2003Date of Patent: June 8, 2004Assignee: Chemagis Ltd.Inventors: Yaacov Rubinsztain, Ariana Segal, Joseph Kaspi, Ori Lerman
-
Publication number: 20040048893Abstract: The invention provides a process for the preparation of a compound of the formula 6 comprising the hydrolysis and decarboxylation of a compound of the formula 5 according to the reaction: 1Type: ApplicationFiled: June 11, 2003Publication date: March 11, 2004Applicant: CHEMAGIS LTDInventors: Ori Lerman, Joseph Kaspi, Oded Arad, Mohammed Alnabari, Yana Sery
-
Publication number: 20040010155Abstract: The invention provides a process for the preparation and isolation of compound of formula 2, comprising the following steps: 1Type: ApplicationFiled: April 4, 2003Publication date: January 15, 2004Applicant: Chemagis Ltd.Inventors: Yaacov Rubinsztain, Ariana Segal, Joseph Kaspi, Ori Lerman
-
Patent number: 6649796Abstract: The invention provides a process for the preparation of diphenylmethylthioacetamide (I) as described in Scheme 4 comprising reacting of the isothiouronium salt or its corresponding base of the formula IV with an acetamide of the formula XCH2CONH2, wherein X represents a halogen, M represents an alkali metal and A represents an anion, in a protic medium at a temperature of less than 100° C.Type: GrantFiled: April 2, 2002Date of Patent: November 18, 2003Assignee: Chemagis, Ltd.Inventors: Vladimir Naddaka, Naim Menashe, Jael Lexner, Shadi Saeed, Joseph Kaspi, Ori Lerman
-
Publication number: 20020183552Abstract: The invention provides a process for the preparation of diphenylmethylthioacetamide (I) as described in Scheme 4 comprising reacting of the isothiouronium salt or its corresponding base of the formula IV with an acetamide of the formula XCH2CONH2, wherein X represents a halogen, M represents an alkali metal and A represents an anion, in a protic medium at a temperature of less than 100° C.Type: ApplicationFiled: April 2, 2002Publication date: December 5, 2002Applicant: CHEMAGIS LTD.Inventors: Vladimir Naddaka, Naim Menashe, Jael Lexner, Shadi Saeed, Joseph Kaspi, Ori Lerman
-
Patent number: 6100400Abstract: The invention provides a process for the preparation of esters [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid, of the formula (I) ##STR1## wherein X represents a halogen atom and R represents a lower alkyl group comprising reacting:(a) a compound of the formula (II) ##STR2## (b) a compound of the formula (III) ##STR3## and (c) a tertiary amine as a solvent and as an acid scavengerat a temperature of at least 100.degree. C., wherein X is a halogen atom, X' is selected from the group consisting of bromine and chlorine and R is a lower alkyl group.Type: GrantFiled: April 15, 1999Date of Patent: August 8, 2000Assignee: Chemiagis, Ltd.Inventors: Ori Lerman, Erez Gal, Joseph Kaspi
-
Patent number: 5874620Abstract: The invention provides a process for the separation of (RR,SS) 2-dimethylaminomethyl-1-(3-methoxyphenyl) cyclohexanol hydrochloride ?(RR,SS)-Tramadol!, from a mixture consisting of (RR,SS) Tramadol and (RS,SR)-2-dimethylaminomethyl-1-(3-methoxyphenyl) cyclohexanol ?(RS,SR)-Tramadol!, which process includes combining the mixture with an electrophilic reagent, the reagent selectively reacting with the hydroxyl group of (RS,SR)-Tramadol, leaving most of the (RR,SS) Tramadol intact, and precipitating the remaining, practically pure (RR,SS) Tramadol from the mixture.Type: GrantFiled: August 14, 1997Date of Patent: February 23, 1999Assignee: Chemagis, Ltd.Inventors: Ori Lerman, Joseph Kaspi, Dov Brenner
-
Patent number: 5672755Abstract: The invention provides a process for the purification and isolation of (RR,SS)-2-dimethylaminomethyl-1-(3-methoxyphenyl)cyclohexanol from mixtures also containing the (RS,SR) isomer comprising reacting the above mixture in a solvent at elevated temperature under acidic conditions, whereby the (RS,SR) isomer is selectively converted to the (RR,SS) isomer, 1-(3-methoxyphenyl)-2-dimethylaminomethylcyclohex-6-ene, 1-(3-methoxyphenyl)-2-dimethyl-aminomethylcyclohex-1-ene or a mixture thereof, selectively precipitating the desired (RR,SS) isomer as an amine acid salt, and recrystallizing the purified product.Type: GrantFiled: November 14, 1996Date of Patent: September 30, 1997Assignee: Chemagis Ltd.Inventors: Ori Lerman, Michael Tennenbaum, Erez Gal, Joseph Kaspi
-
Patent number: 5414129Abstract: A process for the improved purification and separation of trans 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol hydrochloride from a reaction mixture containing the trans isomer, the cis isomer and Grignard reaction side products, comprising combining the mixture with a solution of hydrochloric acid in a low molecular weight alcohol or with gaseous hydrogen chloride in the presence of an organic solvent selected from medium molecular weight alcohols, ketones, esters and ethers or aromatic ethers, to effect the selective precipitation of trans 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol hydrochloride.Type: GrantFiled: September 8, 1993Date of Patent: May 9, 1995Assignee: Chemagis, Ltd.Inventors: Stephen Cherkez, Ori Lerman, Michael Tennenbaum, Hasalia Avner, Tamar Kunyevski
-
Patent number: 4954648Abstract: A method for the bromination of aromatic compounds, including substituted deactivated aromatic compounds, at mild temperature conditions is disclosed. The method comprises reacting an aromatic compound with a bromination agent consisting of bromine-trifluoride and bromine at a temperature ranging between -10.degree. C. and 30.degree. C. The bromination reaction takes place instantaneously and the brominated aromatic compound is separated from the original reactant by known organic chemistry techniques.Type: GrantFiled: May 11, 1989Date of Patent: September 4, 1990Assignees: Ramot University Authority of Applied Research and Industrial Development Ltd., ICL Industries Ltd.Inventors: Ori Lerman, Shlomo Rozen